{"gene":"NFKB1","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":2004,"finding":"IκB kinases (IKKα and IKKβ) phosphorylate IκB proteins, triggering their proteasomal degradation and releasing NF-κB (including p50-containing dimers) for nuclear translocation; IKK activation operates through both cytoplasmic and nuclear steps.","method":"Biochemical pathway analysis and review of kinase assays","journal":"Trends in biochemical sciences","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — repeatedly replicated across multiple labs with in vitro kinase assays, mutagenesis, and functional validation; foundational mechanism of the pathway","pmids":["15102433"],"is_preprint":false},{"year":2004,"finding":"NF-κB p50/RelA (canonical) dimers are sequestered in the cytoplasm by IκB proteins; phosphorylation of IκBα by IKK leads to its ubiquitination and proteasomal degradation, freeing the p50-containing dimer to translocate to the nucleus and activate transcription.","method":"Co-immunoprecipitation, kinase assays, proteasome inhibitor experiments, nuclear translocation assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — canonical mechanism established by multiple labs using reciprocal biochemical and genetic approaches","pmids":["15371334"],"is_preprint":false},{"year":2005,"finding":"Ubiquitination regulates at least three steps in the NF-κB pathway involving p50/NF-κB1: (1) K48-linked ubiquitination-dependent degradation of IκB, (2) proteasomal processing of the p105 precursor to generate p50, and (3) K63-linked ubiquitination-dependent (degradation-independent) activation of IKK.","method":"In vitro ubiquitination assays, cell-free processing assays, mutant ubiquitin complementation","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution and mutagenesis replicated across multiple studies","pmids":["16056267"],"is_preprint":false},{"year":2006,"finding":"NF-κB transcription factors including p50 bind consensus κB DNA sequences at promoter regions; structural studies revealed the RHD (Rel homology domain) mediates dimerization, IκB binding, and sequence-specific DNA binding.","method":"Crystal structure determination, DNA-binding assays, mutagenesis","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple crystal structures resolved across labs defining RHD architecture","pmids":["17072321"],"is_preprint":false},{"year":2012,"finding":"Structural studies of the three-component NF-κB signaling module (NF-κB, IκB, IKK) show that IκB proteins mask the nuclear localization signal of NF-κB dimers including p50 complexes; IKK-mediated phosphorylation of IκBα on Ser32/Ser36 initiates ubiquitin-dependent degradation, liberating the dimer.","method":"X-ray crystallography, cryo-EM, mutagenesis of IκB phosphorylation sites","journal":"Immunological reviews","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple crystal structures with functional validation by mutagenesis replicated across labs","pmids":["22435546"],"is_preprint":false},{"year":2013,"finding":"Structural studies established that NF-κB1 p50 homodimers lack transactivation domains and can function as transcriptional repressors when bound to κB sites; interaction with IκB proteins involves ankyrin repeats that contact the RHD.","method":"Crystal structure, DNA-binding assays, transcriptional reporter assays","journal":"Annual review of biophysics","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures with functional validation across multiple independent studies","pmids":["23495970"],"is_preprint":false},{"year":2010,"finding":"Under hypoxic conditions, NF-κB activation proceeds through a CaMK2-dependent pathway that activates IKK and TAK1 but does not require TAB1/TAB2; critically, IKK-mediated phosphorylation of IκBα under hypoxia does not lead to its degradation because IκBα is sumoylated by SUMO-2/3 on lysine residues normally required for K48-linked polyubiquitination, thereby retaining IκBα and blocking NF-κB1 (p50)-containing dimer release by a novel mechanism.","method":"siRNA knockdown, in vivo sumoylation assays, inhibition of SUMO proteases, IKK kinase assays, reporter assays","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — single lab, multiple orthogonal methods (siRNA, sumoylation assay, kinase assay, reporter) demonstrating the pathway","pmids":["20696840"],"is_preprint":false},{"year":2010,"finding":"DNA double-strand break-initiated NF-κB signaling involves nuclear ATM-mediated phosphorylation of NEMO (NF-κB essential modulator), which serves as the nuclear-to-cytoplasm signal leading to IKK activation and subsequent nuclear translocation of NF-κB dimers including p50.","method":"ATM kinase assays, NEMO sumoylation/ubiquitination assays, genetic ATM knockout experiments, nuclear fractionation","journal":"Cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — established by multiple labs using kinase assays and genetic models, but reviewed rather than primary data in this paper","pmids":["21187855"],"is_preprint":false},{"year":2007,"finding":"NF-κB (including p50-containing dimers) induces expression of the autophagy receptor p62/SQSTM1, which in turn triggers mitophagic clearance of damaged mitochondria bearing NLRP3-activating signals (mtDNA, mtROS), establishing a negative feedback loop whereby NF-κB limits its own inflammasome-promoting activity.","method":"Macrophage-specific p62 conditional knockout, mitochondrial damage assays, IL-1β ELISA, mitophagy imaging, genetic reconstitution","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean conditional KO with defined cellular phenotype, multiple orthogonal readouts (mitophagy imaging, IL-1β measurement, genetic rescue)","pmids":["26919428"],"is_preprint":false},{"year":2010,"finding":"Deletion of NF-κB subunits p50 (NFKB1) and p52 (NFKB2) in mice causes osteopetrosis, establishing that p50-containing NF-κB complexes are required for RANKL-induced osteoclastogenesis and normal bone resorption.","method":"Double knockout mouse model, histological bone analysis, osteoclast differentiation assays","journal":"Cell research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with specific skeletal phenotype replicated across multiple laboratories","pmids":["21079651"],"is_preprint":false},{"year":2016,"finding":"Phosphorylation of NF-κB subunits controls transcription in a gene-specific manner; p50 phosphorylation and that of its dimerization partners determines promoter selectivity and transactivation potential, offering mechanistic basis for selective gene regulation.","method":"Site-directed mutagenesis of phosphorylation sites, reporter gene assays, ChIP","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — review integrating multiple studies with mutagenesis and reporter data, single-gene resolution moderate","pmids":["26999213"],"is_preprint":false},{"year":2003,"finding":"MSK1 kinase phosphorylates NF-κB p65 (RelA) at Ser276 and histone H3 at Ser10 at the IL-6 promoter in response to TNF signaling, establishing MSK1 as the kinase that coordinates transcription factor phosphorylation and histone modification at a single NF-κB target promoter.","method":"In vitro kinase assay, chromatin immunoprecipitation, mutagenesis of Ser276","journal":"Advances in experimental medicine and biology","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro kinase assay and ChIP, single lab; pertains primarily to p65 but defines the signaling context for p50-containing dimers at target promoters","pmids":["14713228"],"is_preprint":false},{"year":2013,"finding":"Phosphorylation and acetylation of p65 at Ser276/Lys310 respectively promote recruitment of Brd4 and P-TEFb to NF-κB target gene promoters, facilitating transcription elongation; p50-containing dimers at anti-inflammatory gene promoters instead depend on the elongation factor DSIF, revealing promoter-specific elongation mechanisms.","method":"ChIP, RNA Pol II elongation assays, Brd4/P-TEFb co-immunoprecipitation, mutagenesis","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and biochemical assays across multiple studies, though reviewed rather than all primary data here","pmids":["23624258"],"is_preprint":false},{"year":2007,"finding":"NF-κB suppresses TNFα-induced JNK activation and apoptosis by transcriptionally upregulating XIAP, A20, and Gadd45β/MYD118 (an inhibitor of MKK7/JNKK2), and by inducing Ferritin heavy chain and Mn-SOD to reduce ROS, establishing a NF-κB→antioxidant/anti-JNK signaling axis.","method":"Reporter gene assays, JNK kinase assays, ROS measurement, apoptosis assays with NF-κB inhibitors","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal assays from multiple labs, but this paper is a review compiling existing data","pmids":["15611622"],"is_preprint":false},{"year":2015,"finding":"NF-κB p65 binding to a conserved κB site (conserved region C) upstream of the PD-1 (PDCD1) gene is required for LPS/TLR-induced PD-1 expression in macrophages; ChIP confirmed NF-κB p65 occupancy at this site following LPS stimulation.","method":"Chromatin immunoprecipitation (ChIP), luciferase reporter assays with κB site mutations, cyclosporin A inhibition, histone modification analysis","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and promoter mutagenesis in a single study; direct p65 (partner of p50) binding confirmed at this site","pmids":["25810391"],"is_preprint":false}],"current_model":"NFKB1 encodes the p50 subunit (processed from the p105 precursor by proteasomal cleavage driven by K48-linked ubiquitination) that forms transcriptional dimers with RelA or other Rel proteins; in the resting state these dimers are sequestered in the cytoplasm by IκB proteins whose ankyrin repeats contact the p50 RHD, and upon IKK-mediated phosphorylation of IκBα (at Ser32/Ser36), ubiquitin-dependent proteasomal degradation of IκBα releases the p50-containing dimer for nuclear translocation, κB-site binding, and context-dependent gene activation or repression—including induction of a delayed NF-κB→p62→mitophagy negative-feedback loop that limits inflammasome activation, and K63-linked/linear ubiquitin-chain-dependent (degradation-independent) IKK activation as an upstream regulatory layer."},"narrative":{"mechanistic_narrative":"NFKB1 encodes the p50 subunit of NF-κB, a master transcription factor that couples inflammatory and stress signals to gene expression [PMID:15371334, PMID:17072321]. p50 is produced by proteasomal processing of the p105 precursor, one of three ubiquitin-dependent steps in the pathway alongside K48-linked degradation of IκB and K63-linked, degradation-independent activation of IKK [PMID:16056267]. Through its Rel homology domain, p50 mediates dimerization, sequence-specific binding to κB DNA sites, and contact with the ankyrin repeats of IκB proteins, which in resting cells mask the dimer's nuclear localization signal and retain it in the cytoplasm [PMID:17072321, PMID:22435546, PMID:23495970]. IKKα/IKKβ phosphorylation of IκBα on Ser32/Ser36 triggers its ubiquitin-dependent degradation, liberating p50-containing dimers for nuclear translocation [PMID:15102433, PMID:15371334, PMID:22435546]; this release can be blocked when IκBα is instead sumoylated, as occurs under hypoxia via a CaMK2/TAK1/IKK route [PMID:20696840], and the pathway can also be initiated by nuclear DNA-damage signaling through ATM-NEMO [PMID:21187855]. Because p50 homodimers lack a transactivation domain, they act as transcriptional repressors at κB sites, while p50 partner dimers drive activation with promoter selectivity set by subunit phosphorylation and elongation factor usage [PMID:23495970, PMID:26999213, PMID:23624258]. Functionally, p50-containing complexes enforce an NF-κB→p62/SQSTM1→mitophagy negative-feedback loop that clears NLRP3-activating damaged mitochondria and limits inflammasome output [PMID:26919428], support an antioxidant/anti-JNK survival program [PMID:15611622], and are genetically required for RANKL-induced osteoclastogenesis and bone resorption [PMID:21079651].","teleology":[{"year":2004,"claim":"Established the canonical activation logic: how a cytoplasmically sequestered p50-containing dimer is released into the nucleus on demand.","evidence":"IKK kinase assays, Co-IP, proteasome inhibition and nuclear translocation assays","pmids":["15102433","15371334"],"confidence":"High","gaps":["Does not resolve which p50 partner dimers are released in which cell contexts","Kinetics of cytoplasmic vs nuclear IKK steps not delineated for p50 specifically"]},{"year":2005,"claim":"Resolved that ubiquitin chains act at three distinct nodes, explaining how the same modification both generates p50 (p105 processing) and controls IκB turnover and IKK activation.","evidence":"In vitro ubiquitination and cell-free processing assays with mutant ubiquitin complementation","pmids":["16056267"],"confidence":"High","gaps":["E3 ligases and DUBs governing each step not fully assigned","Quantitative balance between full p105 processing and degradation unresolved"]},{"year":2006,"claim":"Defined the structural basis for p50 function by showing the RHD performs dimerization, DNA binding, and IκB contact.","evidence":"Crystal structures, DNA-binding assays and mutagenesis","pmids":["17072321"],"confidence":"High","gaps":["Does not explain dimer-specific promoter selectivity in cells"]},{"year":2010,"claim":"Showed the activation pathway can be diverted: hypoxia-driven SUMO-2/3 modification of IκBα blocks its degradation despite IKK phosphorylation, retaining p50 dimers.","evidence":"siRNA knockdown, in vivo sumoylation assays, SUMO-protease inhibition, IKK and reporter assays","pmids":["20696840"],"confidence":"Medium","gaps":["Single-lab mechanism","In vivo physiological relevance of hypoxic IκBα sumoylation not established"]},{"year":2010,"claim":"Demonstrated genotoxic-stress entry into the pathway through nuclear ATM-NEMO signaling feeding back to IKK and p50 nuclear translocation.","evidence":"ATM kinase assays, NEMO modification assays, ATM knockout and nuclear fractionation","pmids":["21187855"],"confidence":"Medium","gaps":["Reviewed rather than primary data","Target genes activated by this route in p50 dimers not specified"]},{"year":2010,"claim":"Provided in vivo proof that p50-containing complexes are physiologically required, via an osteopetrosis phenotype from loss of p50 and p52.","evidence":"p50/p52 double-knockout mice, bone histology and osteoclast differentiation assays","pmids":["21079651"],"confidence":"High","gaps":["Redundancy between p50 and p52 not separated","Direct osteoclast target genes not defined"]},{"year":2013,"claim":"Clarified p50's dual transcriptional output: lacking a transactivation domain, p50 homodimers act as κB-site repressors while heterodimers can activate.","evidence":"Crystal structures, DNA-binding and reporter assays","pmids":["23495970"],"confidence":"High","gaps":["Switch between repressive and activating p50 dimer states in vivo not mapped"]},{"year":2016,"claim":"Linked the inflammatory output to a self-limiting program in which NF-κB induces p62/SQSTM1 to drive mitophagy and restrain NLRP3 inflammasome activation.","evidence":"Macrophage p62 conditional knockout, mitophagy imaging, IL-1β ELISA and genetic reconstitution","pmids":["26919428"],"confidence":"High","gaps":["Specific p50 dimer driving p62 induction not isolated","Temporal control of the delayed feedback loop not fully defined"]},{"year":2016,"claim":"Built mechanism for selective gene regulation by showing subunit phosphorylation and elongation-factor usage set promoter specificity, with anti-inflammatory p50-dimer promoters depending on DSIF.","evidence":"Phosphosite mutagenesis, reporter assays, ChIP and Pol II elongation/Brd4-P-TEFb assays","pmids":["26999213","23624258","14713228"],"confidence":"Medium","gaps":["Reviewed/multi-study integration rather than single primary dataset","Most elongation mechanisms defined for p65; direct p50 contribution less resolved"]},{"year":2007,"claim":"Connected NF-κB to cell survival by defining a transcriptional antioxidant/anti-JNK axis (XIAP, A20, Gadd45β, ferritin, Mn-SOD) suppressing TNFα-induced apoptosis.","evidence":"Reporter, JNK kinase, ROS and apoptosis assays with NF-κB inhibition","pmids":["15611622"],"confidence":"Medium","gaps":["Compiles existing data rather than new primary results","p50-specific contribution to each target not isolated"]},{"year":null,"claim":"It remains unresolved which specific p50 partner dimers govern each target-gene program and how the repressive versus activating switch is selected at individual κB sites in vivo.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No comprehensive map of p50 dimer composition per gene context","Determinants of homodimer repression vs heterodimer activation in vivo unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[3,5,10]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[3,5]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,4]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,4,7]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,4]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[8,13]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,5,10]}],"complexes":["NF-κB p50/RelA dimer","NF-κB p50 homodimer"],"partners":["RELA","NFKBIA","IKBKB","CHUK","IKBKG","NFKB2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P19838","full_name":"Nuclear factor NF-kappa-B p105 subunit","aliases":["DNA-binding factor KBF1","EBP-1","Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1"],"length_aa":968,"mass_kda":105.4,"function":"NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105 P105 is the precursor of the active p50 subunit (Nuclear factor NF-kappa-B p50 subunit) of the nuclear factor NF-kappa-B (PubMed:1423592). Acts as a cytoplasmic retention of attached NF-kappa-B proteins by p105 (PubMed:1423592) Constitutes the active form, which associates with RELA/p65 to form the NF-kappa-B p65-p50 complex to form a transcription factor (PubMed:1740106, PubMed:7830764). Together with RELA/p65, binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions (PubMed:1740106, PubMed:7830764)","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P19838/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NFKB1","classification":"Not Classified","n_dependent_lines":20,"n_total_lines":1208,"dependency_fraction":0.016556291390728478},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000109320","cell_line_id":"CID001699","localizations":[{"compartment":"cytoplasmic","grade":3}],"interactors":[{"gene":"NFKBIA","stoichiometry":10.0},{"gene":"NFKBIB","stoichiometry":10.0},{"gene":"NFKB2","stoichiometry":10.0},{"gene":"IKBKG","stoichiometry":4.0},{"gene":"CHUK","stoichiometry":0.2},{"gene":"IKBKB","stoichiometry":0.2},{"gene":"RELB","stoichiometry":0.2},{"gene":"RELA","stoichiometry":0.2},{"gene":"TOP1MT","stoichiometry":0.2},{"gene":"REL","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001699","total_profiled":1310},"omim":[{"mim_id":"621524","title":"WD REPEAT- AND SOCS BOX-CONTAINING PROTEIN 2; WSB2","url":"https://www.omim.org/entry/621524"},{"mim_id":"619220","title":"IMMUNODEFICIENCY 78 WITH AUTOIMMUNITY AND DEVELOPMENTAL DELAY; IMD78","url":"https://www.omim.org/entry/619220"},{"mim_id":"617687","title":"TBC1 DOMAIN FAMILY, MEMBER 23; TBC1D23","url":"https://www.omim.org/entry/617687"},{"mim_id":"617650","title":"PTGS2 ANTISENSE NFKB1 COMPLEX-MEDIATED EXPRESSION REGULATOR RNA, NONCODING; PACERR","url":"https://www.omim.org/entry/617650"},{"mim_id":"616744","title":"AUTOINFLAMMATORY SYNDROME, FAMILIAL, BEHCET-LIKE 1; AIFBL1","url":"https://www.omim.org/entry/616744"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/NFKB1"},"hgnc":{"alias_symbol":["KBF1","p105","NFKB-p50","p50","NF-kappaB","NFkappaB","NF-kB1"],"prev_symbol":[]},"alphafold":{"accession":"P19838","domains":[{"cath_id":"2.60.40.340","chopping":"42-239","consensus_level":"high","plddt":91.8004,"start":42,"end":239},{"cath_id":"2.60.40.10","chopping":"251-354","consensus_level":"high","plddt":93.4623,"start":251,"end":354},{"cath_id":"1.25.40.20","chopping":"677-754_771-798","consensus_level":"medium","plddt":87.9723,"start":677,"end":798},{"cath_id":"1.10.533.10","chopping":"807-890","consensus_level":"high","plddt":82.3101,"start":807,"end":890}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P19838","model_url":"https://alphafold.ebi.ac.uk/files/AF-P19838-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P19838-F1-predicted_aligned_error_v6.png","plddt_mean":73.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NFKB1","jax_strain_url":"https://www.jax.org/strain/search?query=NFKB1"},"sequence":{"accession":"P19838","fasta_url":"https://rest.uniprot.org/uniprotkb/P19838.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P19838/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P19838"}},"corpus_meta":[{"pmid":"29158945","id":"PMC_29158945","title":"NF-κB signaling in inflammation.","date":"2017","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29158945","citation_count":7155,"is_preprint":false},{"pmid":"15371334","id":"PMC_15371334","title":"Signaling to NF-kappaB.","date":"2004","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/15371334","citation_count":3281,"is_preprint":false},{"pmid":"11875461","id":"PMC_11875461","title":"NF-kappaB at the crossroads of life and death.","date":"2002","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11875461","citation_count":2328,"is_preprint":false},{"pmid":"18029230","id":"PMC_18029230","title":"Signaling to NF-kappaB by Toll-like receptors.","date":"2007","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18029230","citation_count":1975,"is_preprint":false},{"pmid":"17072321","id":"PMC_17072321","title":"Introduction to NF-kappaB: players, pathways, perspectives.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17072321","citation_count":1788,"is_preprint":false},{"pmid":"21772278","id":"PMC_21772278","title":"Crosstalk in NF-κB signaling pathways.","date":"2011","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21772278","citation_count":1592,"is_preprint":false},{"pmid":"26919428","id":"PMC_26919428","title":"NF-κB Restricts Inflammasome Activation via Elimination of Damaged Mitochondria.","date":"2016","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26919428","citation_count":1002,"is_preprint":false},{"pmid":"16056267","id":"PMC_16056267","title":"Ubiquitin signalling in the NF-kappaB pathway.","date":"2005","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16056267","citation_count":1000,"is_preprint":false},{"pmid":"25187272","id":"PMC_25187272","title":"NF-κB, an active player in human cancers.","date":"2014","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/25187272","citation_count":978,"is_preprint":false},{"pmid":"17072327","id":"PMC_17072327","title":"NF-kappaB and the immune response.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17072327","citation_count":957,"is_preprint":false},{"pmid":"21243012","id":"PMC_21243012","title":"NF-κB in immunobiology.","date":"2011","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/21243012","citation_count":907,"is_preprint":false},{"pmid":"23495970","id":"PMC_23495970","title":"Molecular basis of NF-κB signaling.","date":"2013","source":"Annual review of biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/23495970","citation_count":796,"is_preprint":false},{"pmid":"29862377","id":"PMC_29862377","title":"NF-κB in Oxidative Stress.","date":"2017","source":"Current opinion in toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/29862377","citation_count":793,"is_preprint":false},{"pmid":"18479258","id":"PMC_18479258","title":"NF-kappaB in inflammatory bowel disease.","date":"2008","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18479258","citation_count":665,"is_preprint":false},{"pmid":"22435551","id":"PMC_22435551","title":"The noncanonical NF-κB pathway.","date":"2012","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22435551","citation_count":612,"is_preprint":false},{"pmid":"26999213","id":"PMC_26999213","title":"The Regulation of NF-κB Subunits by Phosphorylation.","date":"2016","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/26999213","citation_count":601,"is_preprint":false},{"pmid":"15102433","id":"PMC_15102433","title":"IkappaB kinases: key regulators of the NF-kappaB pathway.","date":"2004","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15102433","citation_count":527,"is_preprint":false},{"pmid":"21502305","id":"PMC_21502305","title":"MicroRNAs in NF-kappaB signaling.","date":"2011","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21502305","citation_count":515,"is_preprint":false},{"pmid":"20651166","id":"PMC_20651166","title":"NF-kappaB in renal inflammation.","date":"2010","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/20651166","citation_count":488,"is_preprint":false},{"pmid":"17072334","id":"PMC_17072334","title":"Inhibitors of NF-kappaB signaling: 785 and counting.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17072334","citation_count":488,"is_preprint":false},{"pmid":"34434197","id":"PMC_34434197","title":"NF-κB: At the Borders of Autoimmunity and Inflammation.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34434197","citation_count":480,"is_preprint":false},{"pmid":"17303919","id":"PMC_17303919","title":"The NF-kappaB regulatory network.","date":"2006","source":"Cardiovascular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/17303919","citation_count":453,"is_preprint":false},{"pmid":"34977871","id":"PMC_34977871","title":"NF-κB signaling in inflammation and cancer.","date":"2021","source":"MedComm","url":"https://pubmed.ncbi.nlm.nih.gov/34977871","citation_count":446,"is_preprint":false},{"pmid":"24004831","id":"PMC_24004831","title":"The NF-κB signalling pathway in osteoarthritis.","date":"2013","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/24004831","citation_count":430,"is_preprint":false},{"pmid":"20516126","id":"PMC_20516126","title":"Oncogenic activation of NF-kappaB.","date":"2010","source":"Cold Spring Harbor perspectives in biology","url":"https://pubmed.ncbi.nlm.nih.gov/20516126","citation_count":422,"is_preprint":false},{"pmid":"10209157","id":"PMC_10209157","title":"Multiple signals converging on NF-kappaB.","date":"1999","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10209157","citation_count":415,"is_preprint":false},{"pmid":"29305014","id":"PMC_29305014","title":"NF-κB and the Transcriptional Control of Inflammation.","date":"2017","source":"International review of cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29305014","citation_count":412,"is_preprint":false},{"pmid":"16918500","id":"PMC_16918500","title":"Naturally occurring NF-kappaB inhibitors.","date":"2006","source":"Mini reviews in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16918500","citation_count":365,"is_preprint":false},{"pmid":"16485028","id":"PMC_16485028","title":"NF-kappaB and IKK as therapeutic targets in cancer.","date":"2006","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/16485028","citation_count":364,"is_preprint":false},{"pmid":"12773372","id":"PMC_12773372","title":"NF-kappaB and virus infection: who controls whom.","date":"2003","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12773372","citation_count":354,"is_preprint":false},{"pmid":"18675321","id":"PMC_18675321","title":"NF-kappaB signaling in cerebral ischemia.","date":"2008","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18675321","citation_count":342,"is_preprint":false},{"pmid":"19823771","id":"PMC_19823771","title":"NF-kappaB and cancer: how intimate is this relationship.","date":"2009","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19823771","citation_count":334,"is_preprint":false},{"pmid":"30236789","id":"PMC_30236789","title":"Redox and NF-κB signaling in osteoarthritis.","date":"2018","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30236789","citation_count":317,"is_preprint":false},{"pmid":"22396894","id":"PMC_22396894","title":"NF-κB in Aging and Disease.","date":"2011","source":"Aging and disease","url":"https://pubmed.ncbi.nlm.nih.gov/22396894","citation_count":310,"is_preprint":false},{"pmid":"26513405","id":"PMC_26513405","title":"NF-κB and HIF crosstalk in immune responses.","date":"2015","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/26513405","citation_count":296,"is_preprint":false},{"pmid":"23468073","id":"PMC_23468073","title":"NF-κB signaling and bone resorption.","date":"2013","source":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","url":"https://pubmed.ncbi.nlm.nih.gov/23468073","citation_count":291,"is_preprint":false},{"pmid":"31842396","id":"PMC_31842396","title":"NF-κB Signaling Regulates Physiological and Pathological Chondrogenesis.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31842396","citation_count":270,"is_preprint":false},{"pmid":"21079651","id":"PMC_21079651","title":"Role of NF-κB in the skeleton.","date":"2010","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/21079651","citation_count":270,"is_preprint":false},{"pmid":"20300215","id":"PMC_20300215","title":"Signaling to NF-kappaB: regulation by ubiquitination.","date":"2010","source":"Cold Spring Harbor perspectives in biology","url":"https://pubmed.ncbi.nlm.nih.gov/20300215","citation_count":257,"is_preprint":false},{"pmid":"18931690","id":"PMC_18931690","title":"NF-kappaB signaling, liver disease and hepatoprotective agents.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18931690","citation_count":245,"is_preprint":false},{"pmid":"22435550","id":"PMC_22435550","title":"Regulation of NF-κB by deubiquitinases.","date":"2012","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22435550","citation_count":236,"is_preprint":false},{"pmid":"15102437","id":"PMC_15102437","title":"NF-kappaB: tumor promoter or suppressor?","date":"2004","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/15102437","citation_count":234,"is_preprint":false},{"pmid":"23312890","id":"PMC_23312890","title":"Regulation of NF-κB by ubiquitination.","date":"2013","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23312890","citation_count":221,"is_preprint":false},{"pmid":"16187223","id":"PMC_16187223","title":"NF-kappaB in the survival and plasticity of neurons.","date":"2005","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/16187223","citation_count":219,"is_preprint":false},{"pmid":"27424290","id":"PMC_27424290","title":"More to Life than NF-κB in TNFR1 Signaling.","date":"2016","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27424290","citation_count":211,"is_preprint":false},{"pmid":"12166787","id":"PMC_12166787","title":"NF-kappaB activation and inhibition: a review.","date":"2002","source":"Shock (Augusta, Ga.)","url":"https://pubmed.ncbi.nlm.nih.gov/12166787","citation_count":211,"is_preprint":false},{"pmid":"40562870","id":"PMC_40562870","title":"NF-κB in inflammation and cancer.","date":"2025","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/40562870","citation_count":210,"is_preprint":false},{"pmid":"20457557","id":"PMC_20457557","title":"NF-kappaB in the immune response of Drosophila.","date":"2009","source":"Cold Spring Harbor perspectives in biology","url":"https://pubmed.ncbi.nlm.nih.gov/20457557","citation_count":209,"is_preprint":false},{"pmid":"19046922","id":"PMC_19046922","title":"NF-kappaB modulators in osteolytic bone diseases.","date":"2008","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19046922","citation_count":203,"is_preprint":false},{"pmid":"21187855","id":"PMC_21187855","title":"Nuclear initiated NF-κB signaling: NEMO and ATM take center stage.","date":"2010","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/21187855","citation_count":199,"is_preprint":false},{"pmid":"10807322","id":"PMC_10807322","title":"NF-kappaB activation.","date":"2000","source":"Critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10807322","citation_count":197,"is_preprint":false},{"pmid":"22435557","id":"PMC_22435557","title":"MicroRNAs, new effectors and regulators of NF-κB.","date":"2012","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22435557","citation_count":197,"is_preprint":false},{"pmid":"24352326","id":"PMC_24352326","title":"NF-κB control of T cell development.","date":"2014","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24352326","citation_count":196,"is_preprint":false},{"pmid":"22435545","id":"PMC_22435545","title":"NF-κB: where did it come from and why?","date":"2012","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22435545","citation_count":194,"is_preprint":false},{"pmid":"20696840","id":"PMC_20696840","title":"Mechanism of hypoxia-induced NF-kappaB.","date":"2010","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20696840","citation_count":187,"is_preprint":false},{"pmid":"25979753","id":"PMC_25979753","title":"EGFR and NF-κB: partners in cancer.","date":"2015","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25979753","citation_count":186,"is_preprint":false},{"pmid":"14713228","id":"PMC_14713228","title":"A paradigm for gene regulation: inflammation, NF-kappaB and PPAR.","date":"2003","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/14713228","citation_count":186,"is_preprint":false},{"pmid":"28350359","id":"PMC_28350359","title":"NF-κB Signaling in Gastric Cancer.","date":"2017","source":"Toxins","url":"https://pubmed.ncbi.nlm.nih.gov/28350359","citation_count":175,"is_preprint":false},{"pmid":"29315242","id":"PMC_29315242","title":"NF-kappaB: Two Sides of the Same Coin.","date":"2018","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/29315242","citation_count":173,"is_preprint":false},{"pmid":"25690730","id":"PMC_25690730","title":"NF-κB in cancer therapy.","date":"2015","source":"Archives of toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/25690730","citation_count":172,"is_preprint":false},{"pmid":"22052926","id":"PMC_22052926","title":"Blocking NF-κB: an inflammatory issue.","date":"2011","source":"Proceedings of the American Thoracic Society","url":"https://pubmed.ncbi.nlm.nih.gov/22052926","citation_count":169,"is_preprint":false},{"pmid":"22435546","id":"PMC_22435546","title":"NF-κB regulation: lessons from structures.","date":"2012","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22435546","citation_count":168,"is_preprint":false},{"pmid":"31634486","id":"PMC_31634486","title":"NF-κB signaling in skin aging.","date":"2019","source":"Mechanisms of ageing and development","url":"https://pubmed.ncbi.nlm.nih.gov/31634486","citation_count":164,"is_preprint":false},{"pmid":"22543051","id":"PMC_22543051","title":"Diverse ubiquitin signaling in NF-κB activation.","date":"2012","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/22543051","citation_count":157,"is_preprint":false},{"pmid":"19438970","id":"PMC_19438970","title":"NF-kappaB regulation: the nuclear response.","date":"2009","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19438970","citation_count":150,"is_preprint":false},{"pmid":"16524427","id":"PMC_16524427","title":"NF-kappaB activation in melanoma.","date":"2006","source":"Pigment cell research","url":"https://pubmed.ncbi.nlm.nih.gov/16524427","citation_count":146,"is_preprint":false},{"pmid":"24419302","id":"PMC_24419302","title":"NF-κB pathways in hematological malignancies.","date":"2014","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/24419302","citation_count":144,"is_preprint":false},{"pmid":"25810391","id":"PMC_25810391","title":"NF-κB regulates PD-1 expression in macrophages.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25810391","citation_count":144,"is_preprint":false},{"pmid":"32421977","id":"PMC_32421977","title":"Inflammation, NF-κB, and Chronic Diseases: How are They Linked?","date":"2020","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32421977","citation_count":123,"is_preprint":false},{"pmid":"16956585","id":"PMC_16956585","title":"NF-kappaB in solid tumors.","date":"2006","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16956585","citation_count":123,"is_preprint":false},{"pmid":"25473891","id":"PMC_25473891","title":"Critical role of NF-κB in pancreatic cancer.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25473891","citation_count":122,"is_preprint":false},{"pmid":"16965765","id":"PMC_16965765","title":"NF-kappaB activation by double-strand breaks.","date":"2006","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16965765","citation_count":117,"is_preprint":false},{"pmid":"15072771","id":"PMC_15072771","title":"NF-kappaB in cancer--a friend turned foe.","date":"2004","source":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/15072771","citation_count":116,"is_preprint":false},{"pmid":"20848362","id":"PMC_20848362","title":"NF-κB and innate immunity.","date":"2011","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20848362","citation_count":115,"is_preprint":false},{"pmid":"21135870","id":"PMC_21135870","title":"Structural studies of NF-κB signaling.","date":"2010","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/21135870","citation_count":114,"is_preprint":false},{"pmid":"22435558","id":"PMC_22435558","title":"Lessons from mathematically modeling the NF-κB pathway.","date":"2012","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22435558","citation_count":112,"is_preprint":false},{"pmid":"15956359","id":"PMC_15956359","title":"Crossroads of estrogen receptor and NF-kappaB signaling.","date":"2005","source":"Science's STKE : signal transduction knowledge environment","url":"https://pubmed.ncbi.nlm.nih.gov/15956359","citation_count":111,"is_preprint":false},{"pmid":"16626297","id":"PMC_16626297","title":"Regulation of NF-kappaB function.","date":"2006","source":"Biochemical Society symposium","url":"https://pubmed.ncbi.nlm.nih.gov/16626297","citation_count":110,"is_preprint":false},{"pmid":"22435560","id":"PMC_22435560","title":"NF-κB function in B lymphocytes.","date":"2012","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22435560","citation_count":109,"is_preprint":false},{"pmid":"35740272","id":"PMC_35740272","title":"NF-κB: A Double-Edged Sword Controlling Inflammation.","date":"2022","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/35740272","citation_count":108,"is_preprint":false},{"pmid":"22435553","id":"PMC_22435553","title":"The atypical PKCs in inflammation: NF-κB and beyond.","date":"2012","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22435553","citation_count":108,"is_preprint":false},{"pmid":"24450631","id":"PMC_24450631","title":"NF-κB and the cell cycle.","date":"2014","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/24450631","citation_count":105,"is_preprint":false},{"pmid":"28598356","id":"PMC_28598356","title":"NF-κB Signalling in Glioblastoma.","date":"2017","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/28598356","citation_count":102,"is_preprint":false},{"pmid":"32393609","id":"PMC_32393609","title":"Looking Down on NF-κB.","date":"2020","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/32393609","citation_count":100,"is_preprint":false},{"pmid":"17485237","id":"PMC_17485237","title":"Autophagy and NF-kappaB: fight for fate.","date":"2007","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/17485237","citation_count":95,"is_preprint":false},{"pmid":"23624258","id":"PMC_23624258","title":"Transcriptional control by NF-κB: elongation in focus.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23624258","citation_count":94,"is_preprint":false},{"pmid":"15611622","id":"PMC_15611622","title":"NF-kappaB and JNK: an intricate affair.","date":"2004","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/15611622","citation_count":93,"is_preprint":false},{"pmid":"31443240","id":"PMC_31443240","title":"NF-κB Signaling in Ovarian Cancer.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31443240","citation_count":92,"is_preprint":false},{"pmid":"24608805","id":"PMC_24608805","title":"NF-κB in cellular senescence and cancer treatment.","date":"2014","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/24608805","citation_count":92,"is_preprint":false},{"pmid":"29432846","id":"PMC_29432846","title":"NF-κB in pancreatic cancer: Its key role in chemoresistance.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/29432846","citation_count":90,"is_preprint":false},{"pmid":"27452667","id":"PMC_27452667","title":"MALT lymphoma: A paradigm of NF-κB dysregulation.","date":"2016","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/27452667","citation_count":90,"is_preprint":false},{"pmid":"15098063","id":"PMC_15098063","title":"NF-kappaB and reperfusion injury.","date":"2004","source":"Drug news & perspectives","url":"https://pubmed.ncbi.nlm.nih.gov/15098063","citation_count":89,"is_preprint":false},{"pmid":"32486375","id":"PMC_32486375","title":"NF-κB and Its Role in Checkpoint Control.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32486375","citation_count":88,"is_preprint":false},{"pmid":"20151024","id":"PMC_20151024","title":"NF-κB signaling.","date":"2009","source":"Wiley interdisciplinary reviews. Systems biology and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20151024","citation_count":87,"is_preprint":false},{"pmid":"18481952","id":"PMC_18481952","title":"Role of NF-kappaB in beta-cell death.","date":"2008","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/18481952","citation_count":86,"is_preprint":false},{"pmid":"29673141","id":"PMC_29673141","title":"Subunit-Specific Role of NF-κB in Cancer.","date":"2018","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/29673141","citation_count":85,"is_preprint":false},{"pmid":"17530464","id":"PMC_17530464","title":"SUMO and NF-kappaB ties.","date":"2007","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/17530464","citation_count":83,"is_preprint":false},{"pmid":"34025678","id":"PMC_34025678","title":"NF-κB and Its Regulators During Pregnancy.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34025678","citation_count":82,"is_preprint":false},{"pmid":"27308348","id":"PMC_27308348","title":"The role of NF-κB in the pathogenesis of glioma.","date":"2014","source":"Molecular & cellular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27308348","citation_count":80,"is_preprint":false},{"pmid":"18534908","id":"PMC_18534908","title":"Turning NF-kappaB and IRFs on and off in DC.","date":"2008","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18534908","citation_count":79,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":34520,"output_tokens":3525,"usd":0.078217,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11295,"output_tokens":3230,"usd":0.068613,"stage2_stop_reason":"end_turn"},"total_usd":0.14683,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"IκB kinases (IKKα and IKKβ) phosphorylate IκB proteins, triggering their proteasomal degradation and releasing NF-κB (including p50-containing dimers) for nuclear translocation; IKK activation operates through both cytoplasmic and nuclear steps.\",\n      \"method\": \"Biochemical pathway analysis and review of kinase assays\",\n      \"journal\": \"Trends in biochemical sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — repeatedly replicated across multiple labs with in vitro kinase assays, mutagenesis, and functional validation; foundational mechanism of the pathway\",\n      \"pmids\": [\"15102433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"NF-κB p50/RelA (canonical) dimers are sequestered in the cytoplasm by IκB proteins; phosphorylation of IκBα by IKK leads to its ubiquitination and proteasomal degradation, freeing the p50-containing dimer to translocate to the nucleus and activate transcription.\",\n      \"method\": \"Co-immunoprecipitation, kinase assays, proteasome inhibitor experiments, nuclear translocation assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — canonical mechanism established by multiple labs using reciprocal biochemical and genetic approaches\",\n      \"pmids\": [\"15371334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Ubiquitination regulates at least three steps in the NF-κB pathway involving p50/NF-κB1: (1) K48-linked ubiquitination-dependent degradation of IκB, (2) proteasomal processing of the p105 precursor to generate p50, and (3) K63-linked ubiquitination-dependent (degradation-independent) activation of IKK.\",\n      \"method\": \"In vitro ubiquitination assays, cell-free processing assays, mutant ubiquitin complementation\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution and mutagenesis replicated across multiple studies\",\n      \"pmids\": [\"16056267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"NF-κB transcription factors including p50 bind consensus κB DNA sequences at promoter regions; structural studies revealed the RHD (Rel homology domain) mediates dimerization, IκB binding, and sequence-specific DNA binding.\",\n      \"method\": \"Crystal structure determination, DNA-binding assays, mutagenesis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple crystal structures resolved across labs defining RHD architecture\",\n      \"pmids\": [\"17072321\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Structural studies of the three-component NF-κB signaling module (NF-κB, IκB, IKK) show that IκB proteins mask the nuclear localization signal of NF-κB dimers including p50 complexes; IKK-mediated phosphorylation of IκBα on Ser32/Ser36 initiates ubiquitin-dependent degradation, liberating the dimer.\",\n      \"method\": \"X-ray crystallography, cryo-EM, mutagenesis of IκB phosphorylation sites\",\n      \"journal\": \"Immunological reviews\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple crystal structures with functional validation by mutagenesis replicated across labs\",\n      \"pmids\": [\"22435546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Structural studies established that NF-κB1 p50 homodimers lack transactivation domains and can function as transcriptional repressors when bound to κB sites; interaction with IκB proteins involves ankyrin repeats that contact the RHD.\",\n      \"method\": \"Crystal structure, DNA-binding assays, transcriptional reporter assays\",\n      \"journal\": \"Annual review of biophysics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures with functional validation across multiple independent studies\",\n      \"pmids\": [\"23495970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Under hypoxic conditions, NF-κB activation proceeds through a CaMK2-dependent pathway that activates IKK and TAK1 but does not require TAB1/TAB2; critically, IKK-mediated phosphorylation of IκBα under hypoxia does not lead to its degradation because IκBα is sumoylated by SUMO-2/3 on lysine residues normally required for K48-linked polyubiquitination, thereby retaining IκBα and blocking NF-κB1 (p50)-containing dimer release by a novel mechanism.\",\n      \"method\": \"siRNA knockdown, in vivo sumoylation assays, inhibition of SUMO proteases, IKK kinase assays, reporter assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — single lab, multiple orthogonal methods (siRNA, sumoylation assay, kinase assay, reporter) demonstrating the pathway\",\n      \"pmids\": [\"20696840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"DNA double-strand break-initiated NF-κB signaling involves nuclear ATM-mediated phosphorylation of NEMO (NF-κB essential modulator), which serves as the nuclear-to-cytoplasm signal leading to IKK activation and subsequent nuclear translocation of NF-κB dimers including p50.\",\n      \"method\": \"ATM kinase assays, NEMO sumoylation/ubiquitination assays, genetic ATM knockout experiments, nuclear fractionation\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — established by multiple labs using kinase assays and genetic models, but reviewed rather than primary data in this paper\",\n      \"pmids\": [\"21187855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"NF-κB (including p50-containing dimers) induces expression of the autophagy receptor p62/SQSTM1, which in turn triggers mitophagic clearance of damaged mitochondria bearing NLRP3-activating signals (mtDNA, mtROS), establishing a negative feedback loop whereby NF-κB limits its own inflammasome-promoting activity.\",\n      \"method\": \"Macrophage-specific p62 conditional knockout, mitochondrial damage assays, IL-1β ELISA, mitophagy imaging, genetic reconstitution\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean conditional KO with defined cellular phenotype, multiple orthogonal readouts (mitophagy imaging, IL-1β measurement, genetic rescue)\",\n      \"pmids\": [\"26919428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Deletion of NF-κB subunits p50 (NFKB1) and p52 (NFKB2) in mice causes osteopetrosis, establishing that p50-containing NF-κB complexes are required for RANKL-induced osteoclastogenesis and normal bone resorption.\",\n      \"method\": \"Double knockout mouse model, histological bone analysis, osteoclast differentiation assays\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with specific skeletal phenotype replicated across multiple laboratories\",\n      \"pmids\": [\"21079651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Phosphorylation of NF-κB subunits controls transcription in a gene-specific manner; p50 phosphorylation and that of its dimerization partners determines promoter selectivity and transactivation potential, offering mechanistic basis for selective gene regulation.\",\n      \"method\": \"Site-directed mutagenesis of phosphorylation sites, reporter gene assays, ChIP\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — review integrating multiple studies with mutagenesis and reporter data, single-gene resolution moderate\",\n      \"pmids\": [\"26999213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MSK1 kinase phosphorylates NF-κB p65 (RelA) at Ser276 and histone H3 at Ser10 at the IL-6 promoter in response to TNF signaling, establishing MSK1 as the kinase that coordinates transcription factor phosphorylation and histone modification at a single NF-κB target promoter.\",\n      \"method\": \"In vitro kinase assay, chromatin immunoprecipitation, mutagenesis of Ser276\",\n      \"journal\": \"Advances in experimental medicine and biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro kinase assay and ChIP, single lab; pertains primarily to p65 but defines the signaling context for p50-containing dimers at target promoters\",\n      \"pmids\": [\"14713228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Phosphorylation and acetylation of p65 at Ser276/Lys310 respectively promote recruitment of Brd4 and P-TEFb to NF-κB target gene promoters, facilitating transcription elongation; p50-containing dimers at anti-inflammatory gene promoters instead depend on the elongation factor DSIF, revealing promoter-specific elongation mechanisms.\",\n      \"method\": \"ChIP, RNA Pol II elongation assays, Brd4/P-TEFb co-immunoprecipitation, mutagenesis\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and biochemical assays across multiple studies, though reviewed rather than all primary data here\",\n      \"pmids\": [\"23624258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"NF-κB suppresses TNFα-induced JNK activation and apoptosis by transcriptionally upregulating XIAP, A20, and Gadd45β/MYD118 (an inhibitor of MKK7/JNKK2), and by inducing Ferritin heavy chain and Mn-SOD to reduce ROS, establishing a NF-κB→antioxidant/anti-JNK signaling axis.\",\n      \"method\": \"Reporter gene assays, JNK kinase assays, ROS measurement, apoptosis assays with NF-κB inhibitors\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal assays from multiple labs, but this paper is a review compiling existing data\",\n      \"pmids\": [\"15611622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NF-κB p65 binding to a conserved κB site (conserved region C) upstream of the PD-1 (PDCD1) gene is required for LPS/TLR-induced PD-1 expression in macrophages; ChIP confirmed NF-κB p65 occupancy at this site following LPS stimulation.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), luciferase reporter assays with κB site mutations, cyclosporin A inhibition, histone modification analysis\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and promoter mutagenesis in a single study; direct p65 (partner of p50) binding confirmed at this site\",\n      \"pmids\": [\"25810391\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NFKB1 encodes the p50 subunit (processed from the p105 precursor by proteasomal cleavage driven by K48-linked ubiquitination) that forms transcriptional dimers with RelA or other Rel proteins; in the resting state these dimers are sequestered in the cytoplasm by IκB proteins whose ankyrin repeats contact the p50 RHD, and upon IKK-mediated phosphorylation of IκBα (at Ser32/Ser36), ubiquitin-dependent proteasomal degradation of IκBα releases the p50-containing dimer for nuclear translocation, κB-site binding, and context-dependent gene activation or repression—including induction of a delayed NF-κB→p62→mitophagy negative-feedback loop that limits inflammasome activation, and K63-linked/linear ubiquitin-chain-dependent (degradation-independent) IKK activation as an upstream regulatory layer.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"NFKB1 encodes the p50 subunit of NF-κB, a master transcription factor that couples inflammatory and stress signals to gene expression [#1, #3]. p50 is produced by proteasomal processing of the p105 precursor, one of three ubiquitin-dependent steps in the pathway alongside K48-linked degradation of IκB and K63-linked, degradation-independent activation of IKK [#2]. Through its Rel homology domain, p50 mediates dimerization, sequence-specific binding to κB DNA sites, and contact with the ankyrin repeats of IκB proteins, which in resting cells mask the dimer's nuclear localization signal and retain it in the cytoplasm [#3, #4, #5]. IKKα/IKKβ phosphorylation of IκBα on Ser32/Ser36 triggers its ubiquitin-dependent degradation, liberating p50-containing dimers for nuclear translocation [#0, #1, #4]; this release can be blocked when IκBα is instead sumoylated, as occurs under hypoxia via a CaMK2/TAK1/IKK route [#6], and the pathway can also be initiated by nuclear DNA-damage signaling through ATM-NEMO [#7]. Because p50 homodimers lack a transactivation domain, they act as transcriptional repressors at κB sites, while p50 partner dimers drive activation with promoter selectivity set by subunit phosphorylation and elongation factor usage [#5, #10, #12]. Functionally, p50-containing complexes enforce an NF-κB→p62/SQSTM1→mitophagy negative-feedback loop that clears NLRP3-activating damaged mitochondria and limits inflammasome output [#8], support an antioxidant/anti-JNK survival program [#13], and are genetically required for RANKL-induced osteoclastogenesis and bone resorption [#9].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Established the canonical activation logic: how a cytoplasmically sequestered p50-containing dimer is released into the nucleus on demand.\",\n      \"evidence\": \"IKK kinase assays, Co-IP, proteasome inhibition and nuclear translocation assays\",\n      \"pmids\": [\"15102433\", \"15371334\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not resolve which p50 partner dimers are released in which cell contexts\", \"Kinetics of cytoplasmic vs nuclear IKK steps not delineated for p50 specifically\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Resolved that ubiquitin chains act at three distinct nodes, explaining how the same modification both generates p50 (p105 processing) and controls IκB turnover and IKK activation.\",\n      \"evidence\": \"In vitro ubiquitination and cell-free processing assays with mutant ubiquitin complementation\",\n      \"pmids\": [\"16056267\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligases and DUBs governing each step not fully assigned\", \"Quantitative balance between full p105 processing and degradation unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined the structural basis for p50 function by showing the RHD performs dimerization, DNA binding, and IκB contact.\",\n      \"evidence\": \"Crystal structures, DNA-binding assays and mutagenesis\",\n      \"pmids\": [\"17072321\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not explain dimer-specific promoter selectivity in cells\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed the activation pathway can be diverted: hypoxia-driven SUMO-2/3 modification of IκBα blocks its degradation despite IKK phosphorylation, retaining p50 dimers.\",\n      \"evidence\": \"siRNA knockdown, in vivo sumoylation assays, SUMO-protease inhibition, IKK and reporter assays\",\n      \"pmids\": [\"20696840\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab mechanism\", \"In vivo physiological relevance of hypoxic IκBα sumoylation not established\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated genotoxic-stress entry into the pathway through nuclear ATM-NEMO signaling feeding back to IKK and p50 nuclear translocation.\",\n      \"evidence\": \"ATM kinase assays, NEMO modification assays, ATM knockout and nuclear fractionation\",\n      \"pmids\": [\"21187855\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reviewed rather than primary data\", \"Target genes activated by this route in p50 dimers not specified\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Provided in vivo proof that p50-containing complexes are physiologically required, via an osteopetrosis phenotype from loss of p50 and p52.\",\n      \"evidence\": \"p50/p52 double-knockout mice, bone histology and osteoclast differentiation assays\",\n      \"pmids\": [\"21079651\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Redundancy between p50 and p52 not separated\", \"Direct osteoclast target genes not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Clarified p50's dual transcriptional output: lacking a transactivation domain, p50 homodimers act as κB-site repressors while heterodimers can activate.\",\n      \"evidence\": \"Crystal structures, DNA-binding and reporter assays\",\n      \"pmids\": [\"23495970\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Switch between repressive and activating p50 dimer states in vivo not mapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Linked the inflammatory output to a self-limiting program in which NF-κB induces p62/SQSTM1 to drive mitophagy and restrain NLRP3 inflammasome activation.\",\n      \"evidence\": \"Macrophage p62 conditional knockout, mitophagy imaging, IL-1β ELISA and genetic reconstitution\",\n      \"pmids\": [\"26919428\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific p50 dimer driving p62 induction not isolated\", \"Temporal control of the delayed feedback loop not fully defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Built mechanism for selective gene regulation by showing subunit phosphorylation and elongation-factor usage set promoter specificity, with anti-inflammatory p50-dimer promoters depending on DSIF.\",\n      \"evidence\": \"Phosphosite mutagenesis, reporter assays, ChIP and Pol II elongation/Brd4-P-TEFb assays\",\n      \"pmids\": [\"26999213\", \"23624258\", \"14713228\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reviewed/multi-study integration rather than single primary dataset\", \"Most elongation mechanisms defined for p65; direct p50 contribution less resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Connected NF-κB to cell survival by defining a transcriptional antioxidant/anti-JNK axis (XIAP, A20, Gadd45β, ferritin, Mn-SOD) suppressing TNFα-induced apoptosis.\",\n      \"evidence\": \"Reporter, JNK kinase, ROS and apoptosis assays with NF-κB inhibition\",\n      \"pmids\": [\"15611622\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Compiles existing data rather than new primary results\", \"p50-specific contribution to each target not isolated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved which specific p50 partner dimers govern each target-gene program and how the repressive versus activating switch is selected at individual κB sites in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No comprehensive map of p50 dimer composition per gene context\", \"Determinants of homodimer repression vs heterodimer activation in vivo unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [3, 5, 10]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [3, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 4]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 4, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 4]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [8, 13]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 5, 10]}\n    ],\n    \"complexes\": [\"NF-κB p50/RelA dimer\", \"NF-κB p50 homodimer\"],\n    \"partners\": [\"RELA\", \"NFKBIA\", \"IKBKB\", \"CHUK\", \"IKBKG\", \"NFKB2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}